{"id":229540,"date":"2025-02-13T17:27:39","date_gmt":"2025-02-13T16:27:39","guid":{"rendered":"https:\/\/www.qualipath.de\/nuertingen\/?page_id=229540"},"modified":"2026-04-14T11:18:52","modified_gmt":"2026-04-14T09:18:52","slug":"downloads","status":"publish","type":"page","link":"https:\/\/www.qualipath.de\/nuertingen\/downloads\/","title":{"rendered":"Downloads"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8220;1&#8243; admin_label=&#8220;Slider&#8220; _builder_version=&#8220;4.27.4&#8243; _module_preset=&#8220;default&#8220; width=&#8220;100vw&#8220; max_width=&#8220;100vw&#8220; custom_padding=&#8220;0px||0px||false|false&#8220; locked=&#8220;off&#8220; global_colors_info=&#8220;{}&#8220;][et_pb_row _builder_version=&#8220;4.27.4&#8243; _module_preset=&#8220;default&#8220; width=&#8220;90%&#8220; width_tablet=&#8220;100%&#8220; width_phone=&#8220;100%&#8220; width_last_edited=&#8220;on|phone&#8220; custom_margin=&#8220;0px||0px||false|false&#8220; custom_padding=&#8220;0px||0px||false|false&#8220; global_colors_info=&#8220;{}&#8220;][et_pb_column type=&#8220;4_4&#8243; _builder_version=&#8220;4.27.4&#8243; _module_preset=&#8220;default&#8220; global_colors_info=&#8220;{}&#8220;][et_pb_slider show_arrows=&#8220;off&#8220; show_pagination=&#8220;off&#8220; admin_label=&#8220;Slider-Bild&#8220; _builder_version=&#8220;4.27.4&#8243; _module_preset=&#8220;default&#8220; background_enable_image=&#8220;off&#8220; custom_margin=&#8220;||0px||false|false&#8220; auto=&#8220;on&#8220; custom_css_slide_title=&#8220;animation-name:fadeTop;&#8220; custom_css_slide_image=&#8220;animation-name:fadeTop;&#8220; global_colors_info=&#8220;{}&#8220;][et_pb_slide _builder_version=&#8220;4.27.4&#8243; _module_preset=&#8220;default&#8220; background_enable_color=&#8220;off&#8220; background_image=&#8220;https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/02\/qualipath-downloads.jpg&#8220; background_enable_image=&#8220;on&#8220; global_colors_info=&#8220;{}&#8220; sticky_transition=&#8220;on&#8220;][\/et_pb_slide][\/et_pb_slider][et_pb_text admin_label=&#8220;Slider-Headline&#8220; _builder_version=&#8220;4.27.4&#8243; _module_preset=&#8220;default&#8220; text_text_color=&#8220;#1D1D1B&#8220; text_font_size=&#8220;28px&#8220; text_line_height=&#8220;1.2em&#8220; header_4_font=&#8220;|600|||||||&#8220; header_4_text_color=&#8220;#1D1D1B&#8220; header_4_font_size=&#8220;30px&#8220; header_4_line_height=&#8220;1.2em&#8220; background_color=&#8220;RGBA(255,255,255,0)&#8220; use_background_color_gradient=&#8220;on&#8220; background_color_gradient_direction=&#8220;91deg&#8220; background_color_gradient_stops=&#8220;#ffffff 0%|rgba(0,196,163,0) 98%&#8220; positioning=&#8220;absolute&#8220; position_origin_a=&#8220;bottom_left&#8220; z_index=&#8220;500&#8243; width=&#8220;50%&#8220; custom_padding=&#8220;2%|5%|1%|5%|false|true&#8220; animation_style=&#8220;slide&#8220; animation_direction=&#8220;bottom&#8220; animation_intensity_slide=&#8220;5%&#8220; global_colors_info=&#8220;{}&#8220;]<\/p>\n<h1><strong>Downloads<\/strong><\/h1>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8220;1&#8243; admin_label=&#8220;Inhalt&#8220; _builder_version=&#8220;4.27.4&#8243; _module_preset=&#8220;default&#8220; custom_margin=&#8220;0px||0px||false|false&#8220; custom_padding=&#8220;0px||50px||false|false&#8220; animation_style=&#8220;fade&#8220; locked=&#8220;off&#8220; collapsed=&#8220;on&#8220; global_colors_info=&#8220;{}&#8220;][et_pb_row _builder_version=&#8220;4.27.4&#8243; _module_preset=&#8220;default&#8220; width=&#8220;90%&#8220; global_colors_info=&#8220;{}&#8220;][et_pb_column type=&#8220;4_4&#8243; _builder_version=&#8220;4.27.4&#8243; _module_preset=&#8220;default&#8220; global_colors_info=&#8220;{}&#8220;][et_pb_text _builder_version=&#8220;4.27.4&#8243; _module_preset=&#8220;default&#8220; global_colors_info=&#8220;{}&#8220;]<\/p>\n<p>Nachfolgend finden Sie Informationen und Unterlagen zu verschiedenen Themen oder Fachbereichen. <br \/>Sie k\u00f6nnen die Unterlagen als <strong>pdf<\/strong> herunterladen.<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8220;4.27.4&#8243; _module_preset=&#8220;default&#8220; custom_margin=&#8220;||10px||false|false&#8220; global_colors_info=&#8220;{}&#8220;]<\/p>\n<h2>Antr\u00e4ge<\/h2>\n<p>[\/et_pb_text][et_pb_text disabled_on=&#8220;off|off|off&#8220; _builder_version=&#8220;4.27.6&#8243; _module_preset=&#8220;default&#8220; custom_margin=&#8220;||0px||false|false&#8220; link_option_url=&#8220;https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2026\/04\/Begutachtungsantrag-Qualipath-Nuertingen-A4_ab202511.pdf&#8220; link_option_url_new_window=&#8220;on&#8220; global_colors_info=&#8220;{}&#8220;]<\/p>\n<ul>\n<li><strong>Begutachtungsantrag<\/strong><br \/>PDF-Format (620 KB)<strong><\/strong><strong><\/strong><\/li>\n<\/ul>\n<p>[\/et_pb_text][et_pb_text disabled_on=&#8220;off|off|off&#8220; _builder_version=&#8220;4.27.4&#8243; _module_preset=&#8220;default&#8220; custom_margin=&#8220;||0px||false|false&#8220; link_option_url=&#8220;https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/qualipath-nuertingen-obduktionsantrag.pdf&#8220; link_option_url_new_window=&#8220;on&#8220; global_colors_info=&#8220;{}&#8220;]<\/p>\n<ul>\n<li><strong>Obduktionsantrag<\/strong><br \/>PDF-Format (187 KB)<strong><\/strong><strong><\/strong><\/li>\n<\/ul>\n<p>[\/et_pb_text][et_pb_text disabled_on=&#8220;off|off|off&#8220; _builder_version=&#8220;4.27.6&#8243; _module_preset=&#8220;default&#8220; custom_margin=&#8220;||0px||false|false&#8220; link_option_url=&#8220;https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2026\/04\/Materialanforderung-4fach-ab-04022026.pdf&#8220; link_option_url_new_window=&#8220;on&#8220; hover_enabled=&#8220;0&#8243; global_colors_info=&#8220;{}&#8220; sticky_enabled=&#8220;0&#8243;]<\/p>\n<ul>\n<li><strong>Materialanforderung (4-fach)<\/strong><br \/>PDF-Format (110 KB)<\/li>\n<\/ul>\n<p>[\/et_pb_text][et_pb_text disabled_on=&#8220;off|off|off&#8220; _builder_version=&#8220;4.27.4&#8243; _module_preset=&#8220;default&#8220; custom_margin=&#8220;||0px||false|false&#8220; link_option_url=&#8220;https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/qualipath-nuertingen-igel-schein.pdf&#8220; link_option_url_new_window=&#8220;on&#8220; global_colors_info=&#8220;{}&#8220;]<\/p>\n<ul>\n<li><strong>Patientenvereinbarung u\u0308ber eine individuelle Gesundheitsleistung (IGeL)<\/strong><br \/>PDF-Format (91 KB)<\/li>\n<\/ul>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8220;4.27.4&#8243; _module_preset=&#8220;default&#8220; custom_margin=&#8220;30px||10px||false|false&#8220; global_colors_info=&#8220;{}&#8220;]<\/p>\n<h2>Zertifikate<\/h2>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8220;4.27.6&#8243; _module_preset=&#8220;default&#8220; global_colors_info=&#8220;{}&#8220;]<strong>2025<\/strong><\/p>\n<ul>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2026\/04\/Ringversuch-p16-HNSCC-IHC.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;p16 HNSCC (IHC)&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2026\/04\/Ringversuch-defiziente-DNA-Mismatch-Repair-dMMR-Split-1.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;defiziente DNA-Mismatch-Repair (dMMR) Split 1&#8220;<\/strong><\/a><\/li>\n<li><strong><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2026\/04\/Ringversuch-Keratine-Prostatakarzinom.pdf\" target=\"_blank\" rel=\"noopener\">Ringversuch Keratine Prostatakarzinom<\/a><\/strong><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2026\/04\/Ringversuch-Oestrogen-Rezeptor-IHC-Split-1.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch O\u0308strogen-Rezeptor (IHC) Split 1<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2026\/04\/Ringversuch-CD117-IHC.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch CD117-IHC<\/strong><\/a><\/li>\n<\/ul>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8220;4.27.4&#8243; _module_preset=&#8220;default&#8220; global_colors_info=&#8220;{}&#8220;]<\/p>\n<p><strong>2024<\/strong><\/p>\n<ul>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-CD117-IHC-2024.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;CD117 (IHC)&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-defiziente-DNA-Mismatch-Repair-dMMR-Split-2024.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;defiziente DNA-Mismatch Repair (dMMR) Split 2&#8220;<\/strong><\/a><\/li>\n<li><strong><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-Neuroendokrine-Marker.pdf\" target=\"_blank\" rel=\"noopener\">Ringversuch Neuroendokrine Marker<\/a><\/strong><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/12\/Ringversuch-defiziente-DNA-Mismatch-Repair-dMMR-Split-1.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch DNA-Missmatch Repair\u00a0<\/strong><\/a><\/li>\n<\/ul>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8220;4.27.4&#8243; _module_preset=&#8220;default&#8220; global_colors_info=&#8220;{}&#8220;]<\/p>\n<p><strong>2023<\/strong><\/p>\n<ul>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-CD117-IHC-2023.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;CD117 (IHC)&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-defiziente-DNA-Mismatch-Repair-2023.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;defiziente DNA-Mismatch Repair (dMMR) Split 1&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-HER2-Magenkarzinom-2023.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;HER2 Magenkarzinom (IHC)&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-Keratine-Prostatakarzinom-IHC-2023.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;Keratine \/ Prostatakarzinom (IHC)&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-Lymphome-2023.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;Lymphome&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-Mammakarzinom-Oestrogen-IHC-2023.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;Mammakarzinom: \u00d6strogenRezeptor (IHC) Split 1&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-p16-HNSCC-IHC-2023.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;p16 HNSCC (IHC)&#8220;<\/strong><\/a><\/li>\n<li><a href=\"Ringversuch%20PD-L1 Multi-Entita\u0308ten (IHC) (2023)\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;PD-L1 Multi-Entit\u00e4ten (IHC)&#8220;<\/strong><\/a><\/li>\n<\/ul>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8220;4.27.4&#8243; _module_preset=&#8220;default&#8220; global_colors_info=&#8220;{}&#8220;]<\/p>\n<p><strong>2022<\/strong><\/p>\n<ul>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-CD117-IHC-2022.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;CD117 (IHC)&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-defiziente-DNA-Mismatch-Repair-IHC-2022.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;defiziente DNA-Mismatch Repair (IHC)&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-HER2-Magenkarzinom-2022.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;HER2 Magenkarzinom (IHC)&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-KeratineProstatakarzinom-IHC-2022.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;Keratine\/Prostatakarzinom (IHC)&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-Lymphome-2022.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;Lymphome&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-Mammakarzinom-HER2-IHC-2022.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;Mammakarzinom: HER2 (IHC)&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-Mammakarzinom-Oestrogen-IHC-2022.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;Mammakarzinom: \u00d6strogenRezeptor (IHC)&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Rngversuch-Neuroendokrine-Marker-2022.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;Neuroendokrine Marker: Synaptophysin, Chromogranin, MIB1&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-p16-HNSCC-IHC-2022.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;p16 HNSCC (IHC)&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-PD-L1-Magenkarzinom-IHC-2022.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;PD-L1 Magenkarzinom (IHC)&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-PD-L1-NSCLC-IHC-TPS-2022.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;PD-L1 NSCLC (IHC), TPS&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-PD-L1-Oesophaguskarzinom-IHC-2022.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;PD-L1 \u00d6sophaguskarzinom &amp; Karzinome des Gastro\u00f6sophagealen \u00dcbergangs (IHC), CPS &amp; TC&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-PD-L1-TNBC-IHC-2022.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;PD-L1 TNBC (IHC)&#8220;<\/strong><\/a><\/li>\n<\/ul>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8220;4.27.4&#8243; _module_preset=&#8220;default&#8220; global_colors_info=&#8220;{}&#8220;]<\/p>\n<p><strong>2021<\/strong><\/p>\n<ul>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-CD117-IHC-2021.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;CD117 (IHC)&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-HER2-Magenkarzinom-IHC-2021.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;HER2 Magenkarzinom (IHC)&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-Keratine-Prostatakarzinom-IHC-2021.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;Keratine Prostatakarzinom (IHC)&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-Lymphome-2021.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;Lymphome&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-Mammakarzinom-Oestrogen-Rezeptor-IHC-2021.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;Mammakarzinom: \u00d6strogen-Rezeptor (IHC)&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-Neuroendokrine-Marker-IHC-2021.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;Neuroendokrine Marker: Synaptophysin, Chromogranin, MIB1 (IHC)&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-p16-HNSCC-IHC-2021.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;p16 HNSCC (IHC)&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-PD-L1-NSCLC-IHC-TPS-2021.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;PD-L1 NSCLC (IHC), TPS&#8220;<\/strong><\/a><\/li>\n<\/ul>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8220;4.27.4&#8243; _module_preset=&#8220;default&#8220; global_colors_info=&#8220;{}&#8220;]<\/p>\n<p><strong>2020<\/strong><\/p>\n<ul>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Auswerteversuch-ER-Mammakarzinom-2020.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Auswerteversuch &#8222;ER, Mammakarzinom&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Auswerteversuch-HER-2neu-Mammakarzinom-2020.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Auswerteversuch &#8222;HER-2\/neu, Mammakarzinom&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Auswerteversuch-Ki-67-Proliferation-2020.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Auswerteversuch &#8222;Ki-67, Proliferation&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Auswerteversuch-PR-Mammakarzinom_3-2020.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Auswerteversuch &#8222;PR, Mammakarzinom&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-CD117-2020.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;CD117&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-ER-Mammakarzinom-2020.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;ER, Mammakarzinom&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-HER-2neu-Mammakarzinom-2020.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;HER-2\/neu, Mammakarzinom&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-Keratine-Prostata-2020.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;Keratine \/ Prostata&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-Ki-67-Proliferation-2020.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;Ki-67, Proliferation&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-Lymphome-CD20-CyclinD1-CD5-2020.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;Lymphome: CD20, CyclinD1, CD5&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-Mismatch-Repair-De-2020.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;Mismatch-Repair-Dezienz (MMRD)&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-PR-Mammakarzinom-2020.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;PR, Mammakarzinom&#8220;<\/strong><\/a><\/li>\n<\/ul>\n<ul><\/ul>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8220;4.27.4&#8243; _module_preset=&#8220;default&#8220; global_colors_info=&#8220;{}&#8220;]<\/p>\n<p><strong>2019<\/strong><\/p>\n<ul>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Auswerteversuch-ER-Mammakarzinom-2019.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Auswerteversuch &#8222;ER, Mammakarzinom&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Auswerteversuch-HER-2neu-Mammakarzinom-2019.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Auswerteversuch &#8222;HER-2\/neu, Mammakarzinom&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Auswerteversuch-Ki-67-Proliferation-2019.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Auswerteversuch &#8222;Ki-67, Proliferation&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Auswerteversuch-PR-Mammakarzinom-2019.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Auswerteversuch &#8222;PR, Mammakarzinom&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-CD117-2019.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;CD117&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-ER-Mammakarzinom-2019.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;ER, Mammakarzinom&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-HER2-Magen-IHC-2019.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;HER2-Magen IHC&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-HER-2neu-Mammakarzinom-2019.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;HER-2\/neu, Mammakarzinom&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-Keratine-Prostata-2019.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;Keratine \/ Prostata&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-Ki-67-Proliferation-2019.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;Ki-67, Proliferation&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-Lymphome-CD5-CyclinD1-CD23-2019.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;Lymphome: CD5, CyclinD1, CD23&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-Lymphome-CD10-BCL6-2019.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;Lymphome: CD10, BCL6&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-Mismatch-Repair-De-2019.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;Mismatch-Repair-Dezienz (MMRD)&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-Neuroendokrine-Marker-basic-2019.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;Neuroendokrine Marker (basic) &#8211; Synaptophysin, Chromogranin, Mib1&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-PD-L1-NSCLC-2019.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;PD-L1 NSCLC&#8220;<\/strong><strong><\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-PR-Mammakarzinom-2019.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;PR, Mammakarzinom&#8220;<\/strong><\/a><\/li>\n<\/ul>\n<ul><\/ul>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8220;4.27.4&#8243; _module_preset=&#8220;default&#8220; global_colors_info=&#8220;{}&#8220;]<\/p>\n<p><strong>2018<\/strong><\/p>\n<ul>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Auswerteversuch-ER-Mammakarzinom-2018.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Auswerteversuch &#8222;ER, Mammakarzinom&#8220;<\/strong><strong><\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Auswerteversuch-HER-2neu-2018.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Auswerteversuch &#8222;HER-2\/neu, Mammakarzinom&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Auswerteversuch-Ki-67-Proliferation-2018.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Auswerteversuch &#8222;Ki-67, Proliferation&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Auswerteversuch-PR-Mammakarzinom-2018.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Auswerteversuch &#8222;PR, Mammakarzinom&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-CD117-2018.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;CD117&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-ER-Mammakarzinom-2018.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;ER, Mammakarzinom&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-HER2-Magen-IHC-2018.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringervsuch &#8222;HER2-Magen (IHC)&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-HER-2neu-Mammakarzinom-2018.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;HER-2\/neu, Mammakarzinom&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-Keratine-Prostata-2018.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;Keratine \/ Prostata&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-Mismatch-Repair-De-2018.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;Mismatch-Repair-Dezienz II&#8220;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.qualipath.de\/nuertingen\/wp-content\/uploads\/sites\/3\/2025\/05\/Ringversuch-PR-Mammakarzinom-2018.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Ringversuch &#8222;PR, Mammakarzinom&#8220;<\/strong><\/a><strong><\/strong><\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>DownloadsNachfolgend finden Sie Informationen und Unterlagen zu verschiedenen Themen oder Fachbereichen. Sie k\u00f6nnen die Unterlagen als pdf herunterladen.Antr\u00e4ge BegutachtungsantragPDF-Format (620 KB) ObduktionsantragPDF-Format (187 KB) Materialanforderung (4-fach)PDF-Format (110 KB) Patientenvereinbarung u\u0308ber eine individuelle Gesundheitsleistung (IGeL)PDF-Format (91 KB) Zertifikate2025 Ringversuch &#8222;p16 HNSCC (IHC)&#8220; Ringversuch &#8222;defiziente DNA-Mismatch-Repair (dMMR) Split 1&#8220; Ringversuch Keratine Prostatakarzinom Ringversuch O\u0308strogen-Rezeptor (IHC) Split 1 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"dipi_cpt_category":[],"class_list":["post-229540","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.qualipath.de\/nuertingen\/wp-json\/wp\/v2\/pages\/229540","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.qualipath.de\/nuertingen\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.qualipath.de\/nuertingen\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.qualipath.de\/nuertingen\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.qualipath.de\/nuertingen\/wp-json\/wp\/v2\/comments?post=229540"}],"version-history":[{"count":39,"href":"https:\/\/www.qualipath.de\/nuertingen\/wp-json\/wp\/v2\/pages\/229540\/revisions"}],"predecessor-version":[{"id":230494,"href":"https:\/\/www.qualipath.de\/nuertingen\/wp-json\/wp\/v2\/pages\/229540\/revisions\/230494"}],"wp:attachment":[{"href":"https:\/\/www.qualipath.de\/nuertingen\/wp-json\/wp\/v2\/media?parent=229540"}],"wp:term":[{"taxonomy":"dipi_cpt_category","embeddable":true,"href":"https:\/\/www.qualipath.de\/nuertingen\/wp-json\/wp\/v2\/dipi_cpt_category?post=229540"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}